GIST Support International - logo

GIST Support International - GIST In the News
GIST Imagery
Slide presentation from Dr. Peter Reichardt
Dr. Peter Reichardt has generously made available the slides he used at his June 2005 presentation at the meeting "New Horizons in Treating Cancer: Third International Conference for Organizations Representing People with CML or GIST," held in Dublin, Ireland. This presentation summarizes the consensus about GIST diagnosis and treatment from the European Society of Medical Oncology and also summarizes current GIST drug research. This is a pdf file that can be viewed using Adobe Reader (a free program). Read More
Gastrointestinal Stromal Tumours: a report by B. Landuyt & AT Van Oosterom

  Read More
Personalized Medicine Moves Forward
This news release describes the applications of mutation testing to GIST patients, based on research by Dr. Heinrich at Oregon Health Science University. Read More
The Implications of Kinase Mutations in Clinical Practice: An Interview on GIST With Dr. Michael Heinrich

This Medscape interview is free-access, but Medscape requires a simple user registration to view its content.

Read More
Searchable online Canadian database of health product adverse reactions

Read More
Molecular Testing in Patients with Rare Cancer Predicts Response to Gleevec
Dr. Michael Heinrich of Oregon Health Science University discusses how mutation testing can predict an individual GISTer's success with Gleevec. Read More
Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 3/2004, under the auspices of ESMO

Below is an informal summary of a consensus summary on GIST treatment by an international group of GIST experts. The consensus conference to develop this guideline was sponsored by the European Society of Medical Oncology (ESMO) with a grant from Novartis. A meeting was held in March 2004 among 41 experts from 12 countries from around the world (not just Europe). The resulting paper was published in March 2005 in the Annals of Oncology, volume 16 pages 566-578. The paper is not free-access. This is a paper your oncologist should obtain and read. Its purpose is to continue in the path started by the NCCN guidelines (which it cites) to develop a standard of care for GIST.

Read More
FDA Works to Speed the Advent of New, More Effective Personalized Medicines

As part of an agency-wide initiative to speed development of new medical products through the science of pharmacogenomics, the Food and Drug Administration (FDA) today issued a final guidance titled "Pharmacogenomic Data Submissions."

Read More
Study finds new designer drug is potent treatment for chronic myelogenous leukemia

This EurekAlert neww story indicates a trial of AMN107 is coming soon for GIST. AMN107 is a followup to Gleevec being developed by Novartis.

Read More
New point system enhances prognosis for GIST patients

Swedish researchers developed a method of predicting the probability GIST will recur after surgery.

Read More
Tumor size alone not always best for gauging treatment response

Not only can positron emission tomography (PET) help evaluate treatment for gastrointestinal stromal tumors (GIST) by revealing biologic changes such as how the tumor processes the fuel that makes it grow, but CT can indirectly reveal biologic changes as well by analyzing the tumor's density, say researchers from The University of Texas M. D. Anderson Cancer Center in Houston.

Read More
ESMO: Tumor Shrinkage Doesn't Predict Response to Imatinib Therapy in Patients With Gastrointestinal Stromal Tumors

VIENNA, AUSTRIA -- November 4, 2004 -- Lack of progression is the most clinically significant predictor of a patient's response to imatinib in patients with gastrointestinal stromal tumours (GIST), a new analysis shows.

Read More
Lack of progression is the most clinically significant measure of a patient's clinical benefit...

Abstract of presentation by G Demetri, M von Mehren, H Joensuu, S Finketstein, D Huse, B Kiese, K McDougal, S Dimitrijevic, GA Glendenning, C Blanke at the 2004 European Society for Medical Oncology congress.

Read More
Biology of Gastrointestinal Stromal Tumors -- Corless et al. 22 (18): 3813 -- Journal of Clinical Oncology

From the Oregon Health & Science University Cancer Institute, Department of Pathology, and Division of Hematology and Oncology, Oregon Health & Science University and Veterans Affairs Medical Center, Portland, OR; and Department of Pathology, Brigham & Women's Hospital, Boston, MA

Read More
CIW ENA 2004

CIW ENA 2004: "16th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'. "

Read More
World Congress on Gastrointestinal Cancer

World Congress on Gastrointestinal Cancer (Webcasts)

Read More

back to top